Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin [October 2014]

Product Code:
596200302
Release Date:
October 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Rheumatoid Arthritis: Roche’s RoACTEMRA (tocilizumab), Janssen Biologics’ golimumab (Simponi), anti-IL6 monoclonals sarilumab and sirukumab; Xeljanz, Oral JAK inhibitors, Biosimilars

Highlights from this event update bulletin

  • How will the EU label expansion for RoActemra (tocilizumab) influence prescribing?
  • Will results from the phase III AVERT study with Orencia (abatacept) change the way the drug is prescribed?
  • Will two-year data from Xeljanz (tofacitinib) ORAL Start study change the way this agent is prescribed?
  • Will sarilumab be able to compete with RoActemra?
  • How is Coherus' etanercept biosimilar, CHS 0214, viewed?
  • Will earlier time point phase III data of BOW 015 add any value?
  • How is approval extrapolation of biosimilars viewed?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved